Intesa Sanpaolo reports no share buybacks between August 11 and August 15, 2025

Gian Maria Gros-Pietro Chairman of the Board of Directors of Intesa Sanpaolo Wikipedia
Gian Maria Gros-Pietro Chairman of the Board of Directors of Intesa Sanpaolo - Wikipedia
0Comments

Intesa Sanpaolo announced that it did not purchase any of its own shares between 11 August and 15 August 2025 as part of its ongoing buyback programme. The bank had previously informed the market about the launch of this programme on 26 May 2025, with operations starting on 2 June 2025.

The transactions were to be executed by Morgan Stanley Europe SE, which was appointed as an independent third-party intermediary. The purchases would have taken place on the Euronext Milan regulated market managed by Borsa Italiana.

According to Intesa Sanpaolo, “on the basis of information provided by Morgan Stanley Europe SE, the third-party intermediary appointed to execute the programme in full independence and without any involvement of the Intesa Sanpaolo Group – from 11 August to 15 August 2025 the Bank executed the purchase transactions summarised in the table below on the regulated market Euronext Milan managed by Borsa Italiana.”

The bank further stated, “From 11 August to 15 August 2025, Intesa Sanpaolo did not purchase any shares.”



1 Comments
  • www.binance.info anmelden says:
    Your comment is awaiting moderation. This is a preview; your comment will be visible after it has been approved.
    Can you be more specific about the content of your article? After reading it, I still have some doubts. Hope you can help me. https://www.binance.info/register?ref=IHJUI7TF
  • Related

    Paul Hudson Chief Executive Officer Sanofi SA

    Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

    Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

    Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

    Volvo announces updated share and vote count after series conversion

    The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

    Paul Hudson Chief Executive Officer Sanofi SA

    Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

    Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

    Trending

    The Weekly Newsletter

    Sign-up for the Weekly Newsletter from EU Business Daily.